VYNE Therapeutics Inc.
VYNEDrugs in Pipeline
16
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
16dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
FMX101
Acne Vulgaris
FMX103 1.5%
Papulopustular Rosacea
FMX-101, 4% minocycline foam
Acne Vulgaris
FMX103 minocycline foam 1.5%
Facial Papulopustular Rosacea
5mg Serlopitant Tablets
Pruritus
Topical Minocycline Foam FXFM244
Acne Vulgaris
serlopitant
Prurigo Nodularis
5 mg Serlopitant Tablets
Pruritus
VYN201 Gel
Non-segmental Vitiligo
FMX114
Atopic Dermatitis
Serlopitant High Dose
Pruritus
FMX-103 1.5%
Rosacea
3% Minocycline Foam
Acne Vulgaris
FDX104 (4% Doxycycline)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
VPD-737
Chronic Pruritus
MK0594
Urinary Incontinence
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FMX101 | Phase 3 | Acne Vulgaris | - | - |
FMX103 1.5% | Phase 3 | Papulopustular Rosacea | - | - |
FMX-101, 4% minocycline foam | Phase 3 | Acne Vulgaris | - | - |
FMX103 minocycline foam 1.5% | Phase 3 | Facial Papulopustular Rosacea | - | - |
5mg Serlopitant Tablets | Phase 3 | Pruritus | - | - |
Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris | - | - |
serlopitant | Phase 2 | Prurigo Nodularis | - | - |
5 mg Serlopitant Tablets | Phase 2 | Pruritus | - | - |
VYN201 Gel | Phase 2 | Non-segmental Vitiligo | - | - |
FMX114 | Phase 2 | Atopic Dermatitis | - | - |
Serlopitant High Dose | Phase 2 | Pruritus | - | - |
FMX-103 1.5% | Phase 2 | Rosacea | - | - |
3% Minocycline Foam | Phase 2 | Acne Vulgaris | - | - |
FDX104 (4% Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors | - | - |
VPD-737 | Phase 2 | Chronic Pruritus | - | - |
MK0594 | Phase 2 | Urinary Incontinence | - | - |
Acne Vulgaris
5 drugs in this indication
Pruritus
5 drugs in this indication
Rash Due to Epidermal Growth Factor Receptor Inhibitors
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Chronic Pruritus
1 drug in this indication
Papulopustular Rosacea
1 drug in this indication
Rosacea
1 drug in this indication
Urinary Incontinence
1 drug in this indication
Facial Papulopustular Rosacea
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in VYNE Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in VYNE Therapeutics Inc.'s (VYNE) pipeline across Phase 3, Phase 2. Its lead program is FMX101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VYNE Therapeutics Inc.'s next FDA catalyst?→
VYNE Therapeutics Inc.'s (VYNE) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VYNE biotech catalysts?→
Add VYNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VYNE Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.